Amyloidosis other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Hardik Patel (talk | contribs) |
No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Amyloidosis}} | {{Amyloidosis}} | ||
{{CMG}} | {{CMG}} {{shyam}} | ||
==Overview== | ==Overview== | ||
Tissue [[ | Tissue [[doppler]] echocardiography and myocardial strain rate imaging has been shown to be very sensitive for the assessment of myocardial dysfunction in [[restrictive cardiomyopathy]]. The developmend of [[serum amyloid P component]] (SAP) scans has given physicians the ability to specifically locate [[amyloid]] deposits. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
*In addition, all [[amyloid]] deposits contain [[serum amyloid P component]] (SAP), a circulating protein of the [[pentraxin]] family. [[Radionuclide]] SAP scans have been developed which can anatomically localize amyloid deposits in patients. | *In addition, all [[amyloid]] deposits contain [[serum amyloid P component]] (SAP), a circulating protein of the [[pentraxin]] family. [[Radionuclide]] SAP scans have been developed which can anatomically localize amyloid deposits in patients.<ref name="pmid22867744">{{cite journal| author=Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW et al.| title=Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. | journal=J Immunol Methods | year= 2012 | volume= 384 | issue= 1-2 | pages= 92-102 | pmid=22867744 | doi=10.1016/j.jim.2012.07.013 | pmc=4068106 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22867744 }} </ref> | ||
*Tissue [[ | *Tissue [[doppler]] and myocardial strain rate imaging has been proven to be very sensitive for the assessment of myocardial dysfunction in [[restrictive cardiomyopathy]]. Doppler studies may show abnormal wall motion early in the disease process. | ||
*Abdominal [[ultrasound]] may reveal a swollen [[liver]] or [[spleen]]. | *Abdominal [[ultrasound]] may reveal a swollen [[liver]] or [[spleen]]. | ||
*Thyroid ultrasound can help diagnose thyroidal involvement by amyloidosis. | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WH}} | |||
{{WS}} | |||
Latest revision as of 18:54, 1 November 2019
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis other imaging findings On the Web |
|
American Roentgen Ray Society Images of Amyloidosis other imaging findings |
|
Risk calculators and risk factors for Amyloidosis other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Tissue doppler echocardiography and myocardial strain rate imaging has been shown to be very sensitive for the assessment of myocardial dysfunction in restrictive cardiomyopathy. The developmend of serum amyloid P component (SAP) scans has given physicians the ability to specifically locate amyloid deposits.
Other Imaging Findings
- In addition, all amyloid deposits contain serum amyloid P component (SAP), a circulating protein of the pentraxin family. Radionuclide SAP scans have been developed which can anatomically localize amyloid deposits in patients.[1]
- Tissue doppler and myocardial strain rate imaging has been proven to be very sensitive for the assessment of myocardial dysfunction in restrictive cardiomyopathy. Doppler studies may show abnormal wall motion early in the disease process.
- Abdominal ultrasound may reveal a swollen liver or spleen.
- Thyroid ultrasound can help diagnose thyroidal involvement by amyloidosis.
References
- ↑ Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW; et al. (2012). "Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use". J Immunol Methods. 384 (1–2): 92–102. doi:10.1016/j.jim.2012.07.013. PMC 4068106. PMID 22867744.